nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—CYP3A7—Progesterone—uterine cancer	0.1	0.14	CbGbCtD
Ondansetron—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.1	0.14	CbGbCtD
Ondansetron—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0759	0.106	CbGbCtD
Ondansetron—CYP3A5—Progesterone—uterine cancer	0.075	0.105	CbGbCtD
Ondansetron—CYP1A2—Progesterone—uterine cancer	0.0558	0.0782	CbGbCtD
Ondansetron—CYP2C9—Progesterone—uterine cancer	0.0503	0.0704	CbGbCtD
Ondansetron—CYP2D6—Progesterone—uterine cancer	0.046	0.0644	CbGbCtD
Ondansetron—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0441	0.0618	CbGbCtD
Ondansetron—CYP2E1—Etoposide—uterine cancer	0.0432	0.0605	CbGbCtD
Ondansetron—CYP3A5—Etoposide—uterine cancer	0.0336	0.047	CbGbCtD
Ondansetron—CYP3A4—Progesterone—uterine cancer	0.0292	0.0409	CbGbCtD
Ondansetron—CYP1A2—Etoposide—uterine cancer	0.025	0.035	CbGbCtD
Ondansetron—CYP2D6—Doxorubicin—uterine cancer	0.014	0.0197	CbGbCtD
Ondansetron—CYP3A4—Etoposide—uterine cancer	0.0131	0.0183	CbGbCtD
Ondansetron—CYP3A4—Doxorubicin—uterine cancer	0.00892	0.0125	CbGbCtD
Ondansetron—SLC47A2—renal system—uterine cancer	0.00366	0.0991	CbGeAlD
Ondansetron—HTR1B—artery—uterine cancer	0.00311	0.0843	CbGeAlD
Ondansetron—SLC47A2—vagina—uterine cancer	0.00265	0.0718	CbGeAlD
Ondansetron—SLC47A1—myometrium—uterine cancer	0.00176	0.0477	CbGeAlD
Ondansetron—SLC47A1—uterine cervix—uterine cancer	0.00137	0.0371	CbGeAlD
Ondansetron—SLC47A1—decidua—uterine cancer	0.0013	0.0353	CbGeAlD
Ondansetron—SLC47A1—renal system—uterine cancer	0.00128	0.0347	CbGeAlD
Ondansetron—SLC47A1—endometrium—uterine cancer	0.00124	0.0335	CbGeAlD
Ondansetron—SLC47A1—mammalian vulva—uterine cancer	0.0012	0.0324	CbGeAlD
Ondansetron—SLC47A1—uterus—uterine cancer	0.00114	0.0309	CbGeAlD
Ondansetron—KCNH2—myometrium—uterine cancer	0.00108	0.0292	CbGeAlD
Ondansetron—SLC47A1—female reproductive system—uterine cancer	0.00103	0.0278	CbGeAlD
Ondansetron—SLC47A1—female gonad—uterine cancer	0.000934	0.0253	CbGeAlD
Ondansetron—SLC47A1—vagina—uterine cancer	0.000928	0.0251	CbGeAlD
Ondansetron—HTR1A—renal system—uterine cancer	0.000883	0.0239	CbGeAlD
Ondansetron—HTR1B—female reproductive system—uterine cancer	0.000876	0.0237	CbGeAlD
Ondansetron—KCNH2—uterine cervix—uterine cancer	0.00084	0.0228	CbGeAlD
Ondansetron—KCNH2—renal system—uterine cancer	0.000786	0.0213	CbGeAlD
Ondansetron—KCNH2—endometrium—uterine cancer	0.00076	0.0206	CbGeAlD
Ondansetron—KCNH2—uterus—uterine cancer	0.0007	0.019	CbGeAlD
Ondansetron—CYP3A5—uterine cervix—uterine cancer	0.000694	0.0188	CbGeAlD
Ondansetron—CYP1A2—renal system—uterine cancer	0.000673	0.0182	CbGeAlD
Ondansetron—CYP3A5—renal system—uterine cancer	0.000649	0.0176	CbGeAlD
Ondansetron—KCNH2—female reproductive system—uterine cancer	0.000629	0.017	CbGeAlD
Ondansetron—CYP2E1—renal system—uterine cancer	0.000605	0.0164	CbGeAlD
Ondansetron—Neoplasm malignant—Doxorubicin—uterine cancer	0.000601	0.00244	CcSEcCtD
Ondansetron—SLC47A1—lymph node—uterine cancer	0.0006	0.0163	CbGeAlD
Ondansetron—Erythema—Dactinomycin—uterine cancer	0.000598	0.00243	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Progesterone—uterine cancer	0.000596	0.00242	CcSEcCtD
Ondansetron—Fatigue—Progesterone—uterine cancer	0.000595	0.00242	CcSEcCtD
Ondansetron—Dyskinesia—Epirubicin—uterine cancer	0.00059	0.0024	CcSEcCtD
Ondansetron—Constipation—Progesterone—uterine cancer	0.00059	0.0024	CcSEcCtD
Ondansetron—Pain—Progesterone—uterine cancer	0.00059	0.0024	CcSEcCtD
Ondansetron—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000585	0.00238	CcSEcCtD
Ondansetron—Cardiovascular disorder—Doxorubicin—uterine cancer	0.000584	0.00237	CcSEcCtD
Ondansetron—KCNH2—female gonad—uterine cancer	0.000573	0.0155	CbGeAlD
Ondansetron—KCNH2—vagina—uterine cancer	0.000569	0.0154	CbGeAlD
Ondansetron—Feeling abnormal—Progesterone—uterine cancer	0.000569	0.00231	CcSEcCtD
Ondansetron—Ventricular extrasystoles—Doxorubicin—uterine cancer	0.000568	0.00231	CcSEcCtD
Ondansetron—Gastrointestinal pain—Progesterone—uterine cancer	0.000565	0.00229	CcSEcCtD
Ondansetron—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000562	0.00228	CcSEcCtD
Ondansetron—Musculoskeletal pain—Epirubicin—uterine cancer	0.000562	0.00228	CcSEcCtD
Ondansetron—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000558	0.00227	CcSEcCtD
Ondansetron—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000556	0.00226	CcSEcCtD
Ondansetron—Hiccups—Epirubicin—uterine cancer	0.000555	0.00225	CcSEcCtD
Ondansetron—Hepatocellular injury—Epirubicin—uterine cancer	0.000555	0.00225	CcSEcCtD
Ondansetron—Ill-defined disorder—Dactinomycin—uterine cancer	0.000555	0.00225	CcSEcCtD
Ondansetron—Injection site reaction—Epirubicin—uterine cancer	0.000552	0.00224	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000549	0.00223	CcSEcCtD
Ondansetron—Urticaria—Progesterone—uterine cancer	0.000549	0.00223	CcSEcCtD
Ondansetron—Dyskinesia—Doxorubicin—uterine cancer	0.000546	0.00222	CcSEcCtD
Ondansetron—Acute coronary syndrome—Etoposide—uterine cancer	0.000546	0.00222	CcSEcCtD
Ondansetron—Abdominal pain—Progesterone—uterine cancer	0.000546	0.00222	CcSEcCtD
Ondansetron—Body temperature increased—Progesterone—uterine cancer	0.000546	0.00222	CcSEcCtD
Ondansetron—Myocardial infarction—Etoposide—uterine cancer	0.000543	0.00221	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00054	0.00219	CcSEcCtD
Ondansetron—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000539	0.00219	CcSEcCtD
Ondansetron—Malaise—Dactinomycin—uterine cancer	0.000539	0.00219	CcSEcCtD
Ondansetron—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000535	0.00217	CcSEcCtD
Ondansetron—Hepatobiliary disease—Etoposide—uterine cancer	0.000524	0.00213	CcSEcCtD
Ondansetron—Musculoskeletal pain—Doxorubicin—uterine cancer	0.00052	0.00211	CcSEcCtD
Ondansetron—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000516	0.00209	CcSEcCtD
Ondansetron—Hiccups—Doxorubicin—uterine cancer	0.000513	0.00209	CcSEcCtD
Ondansetron—Hepatocellular injury—Doxorubicin—uterine cancer	0.000513	0.00209	CcSEcCtD
Ondansetron—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000512	0.00208	CcSEcCtD
Ondansetron—CYP2C9—female reproductive system—uterine cancer	0.000512	0.0139	CbGeAlD
Ondansetron—Injection site reaction—Doxorubicin—uterine cancer	0.00051	0.00207	CcSEcCtD
Ondansetron—Hypersensitivity—Progesterone—uterine cancer	0.000509	0.00207	CcSEcCtD
Ondansetron—Discomfort—Dactinomycin—uterine cancer	0.000503	0.00204	CcSEcCtD
Ondansetron—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000497	0.00202	CcSEcCtD
Ondansetron—Asthenia—Progesterone—uterine cancer	0.000495	0.00201	CcSEcCtD
Ondansetron—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000495	0.00201	CcSEcCtD
Ondansetron—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000495	0.00201	CcSEcCtD
Ondansetron—Pruritus—Progesterone—uterine cancer	0.000488	0.00198	CcSEcCtD
Ondansetron—CYP3A4—renal system—uterine cancer	0.000487	0.0132	CbGeAlD
Ondansetron—CYP2E1—female reproductive system—uterine cancer	0.000485	0.0131	CbGeAlD
Ondansetron—CYP2D6—renal system—uterine cancer	0.000479	0.013	CbGeAlD
Ondansetron—CYP3A5—female gonad—uterine cancer	0.000473	0.0128	CbGeAlD
Ondansetron—Diarrhoea—Progesterone—uterine cancer	0.000472	0.00192	CcSEcCtD
Ondansetron—CYP3A5—vagina—uterine cancer	0.00047	0.0127	CbGeAlD
Ondansetron—Erythema multiforme—Etoposide—uterine cancer	0.00047	0.00191	CcSEcCtD
Ondansetron—Eye disorder—Etoposide—uterine cancer	0.000465	0.00189	CcSEcCtD
Ondansetron—Flushing—Etoposide—uterine cancer	0.000461	0.00187	CcSEcCtD
Ondansetron—Cardiac disorder—Etoposide—uterine cancer	0.000461	0.00187	CcSEcCtD
Ondansetron—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000461	0.00187	CcSEcCtD
Ondansetron—Dizziness—Progesterone—uterine cancer	0.000457	0.00186	CcSEcCtD
Ondansetron—Angiopathy—Etoposide—uterine cancer	0.000451	0.00183	CcSEcCtD
Ondansetron—Immune system disorder—Etoposide—uterine cancer	0.000449	0.00182	CcSEcCtD
Ondansetron—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000449	0.00182	CcSEcCtD
Ondansetron—Hepatic failure—Epirubicin—uterine cancer	0.000448	0.00182	CcSEcCtD
Ondansetron—Mediastinal disorder—Etoposide—uterine cancer	0.000448	0.00182	CcSEcCtD
Ondansetron—Chills—Etoposide—uterine cancer	0.000446	0.00181	CcSEcCtD
Ondansetron—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000443	0.0018	CcSEcCtD
Ondansetron—Vomiting—Progesterone—uterine cancer	0.000439	0.00178	CcSEcCtD
Ondansetron—Rash—Progesterone—uterine cancer	0.000435	0.00177	CcSEcCtD
Ondansetron—Dermatitis—Progesterone—uterine cancer	0.000435	0.00177	CcSEcCtD
Ondansetron—Headache—Progesterone—uterine cancer	0.000433	0.00176	CcSEcCtD
Ondansetron—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000428	0.00174	CcSEcCtD
Ondansetron—Fatigue—Dactinomycin—uterine cancer	0.000421	0.00171	CcSEcCtD
Ondansetron—Pain—Dactinomycin—uterine cancer	0.000417	0.0017	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Epirubicin—uterine cancer	0.000416	0.00169	CcSEcCtD
Ondansetron—Hepatic failure—Doxorubicin—uterine cancer	0.000415	0.00169	CcSEcCtD
Ondansetron—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000414	0.00168	CcSEcCtD
Ondansetron—Feeling abnormal—Dactinomycin—uterine cancer	0.000402	0.00163	CcSEcCtD
Ondansetron—Ill-defined disorder—Etoposide—uterine cancer	0.000402	0.00163	CcSEcCtD
Ondansetron—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000399	0.00162	CcSEcCtD
Ondansetron—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000398	0.00162	CcSEcCtD
Ondansetron—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000394	0.0016	CcSEcCtD
Ondansetron—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000394	0.0016	CcSEcCtD
Ondansetron—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000392	0.00159	CcSEcCtD
Ondansetron—Malaise—Etoposide—uterine cancer	0.00039	0.00159	CcSEcCtD
Ondansetron—CYP3A4—female reproductive system—uterine cancer	0.00039	0.0106	CbGeAlD
Ondansetron—Abdominal pain—Dactinomycin—uterine cancer	0.000386	0.00157	CcSEcCtD
Ondansetron—Body temperature increased—Dactinomycin—uterine cancer	0.000386	0.00157	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.000385	0.00156	CcSEcCtD
Ondansetron—CYP2D6—female reproductive system—uterine cancer	0.000384	0.0104	CbGeAlD
Ondansetron—Loss of consciousness—Etoposide—uterine cancer	0.00038	0.00155	CcSEcCtD
Ondansetron—Cough—Etoposide—uterine cancer	0.000378	0.00153	CcSEcCtD
Ondansetron—Convulsion—Etoposide—uterine cancer	0.000375	0.00152	CcSEcCtD
Ondansetron—Liver function test abnormal—Epirubicin—uterine cancer	0.000372	0.00151	CcSEcCtD
Ondansetron—Chest pain—Etoposide—uterine cancer	0.000368	0.0015	CcSEcCtD
Ondansetron—KCNH2—lymph node—uterine cancer	0.000368	0.00997	CbGeAlD
Ondansetron—Hypokalaemia—Epirubicin—uterine cancer	0.000367	0.00149	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000366	0.00149	CcSEcCtD
Ondansetron—Discomfort—Etoposide—uterine cancer	0.000364	0.00148	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000363	0.00147	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000363	0.00147	CcSEcCtD
Ondansetron—Hypersensitivity—Dactinomycin—uterine cancer	0.00036	0.00146	CcSEcCtD
Ondansetron—Anaphylactic shock—Etoposide—uterine cancer	0.000353	0.00144	CcSEcCtD
Ondansetron—Asthenia—Dactinomycin—uterine cancer	0.00035	0.00142	CcSEcCtD
Ondansetron—CYP2D6—female gonad—uterine cancer	0.000349	0.00946	CbGeAlD
Ondansetron—Asthma—Epirubicin—uterine cancer	0.000348	0.00141	CcSEcCtD
Ondansetron—Tachycardia—Etoposide—uterine cancer	0.000345	0.0014	CcSEcCtD
Ondansetron—Liver function test abnormal—Doxorubicin—uterine cancer	0.000344	0.0014	CcSEcCtD
Ondansetron—Skin disorder—Etoposide—uterine cancer	0.000343	0.00139	CcSEcCtD
Ondansetron—Hypokalaemia—Doxorubicin—uterine cancer	0.000339	0.00138	CcSEcCtD
Ondansetron—Angina pectoris—Epirubicin—uterine cancer	0.000339	0.00138	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000336	0.00136	CcSEcCtD
Ondansetron—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000336	0.00136	CcSEcCtD
Ondansetron—Diarrhoea—Dactinomycin—uterine cancer	0.000334	0.00136	CcSEcCtD
Ondansetron—Hypotension—Etoposide—uterine cancer	0.00033	0.00134	CcSEcCtD
Ondansetron—Dysuria—Epirubicin—uterine cancer	0.000326	0.00132	CcSEcCtD
Ondansetron—Asthma—Doxorubicin—uterine cancer	0.000322	0.00131	CcSEcCtD
Ondansetron—Paraesthesia—Etoposide—uterine cancer	0.000317	0.00129	CcSEcCtD
Ondansetron—Dyspnoea—Etoposide—uterine cancer	0.000315	0.00128	CcSEcCtD
Ondansetron—Somnolence—Etoposide—uterine cancer	0.000314	0.00128	CcSEcCtD
Ondansetron—Angina pectoris—Doxorubicin—uterine cancer	0.000314	0.00128	CcSEcCtD
Ondansetron—Drowsiness—Epirubicin—uterine cancer	0.00031	0.00126	CcSEcCtD
Ondansetron—Vomiting—Dactinomycin—uterine cancer	0.00031	0.00126	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000308	0.00125	CcSEcCtD
Ondansetron—Rash—Dactinomycin—uterine cancer	0.000308	0.00125	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Etoposide—uterine cancer	0.000305	0.00124	CcSEcCtD
Ondansetron—Fatigue—Etoposide—uterine cancer	0.000305	0.00124	CcSEcCtD
Ondansetron—Pain—Etoposide—uterine cancer	0.000302	0.00123	CcSEcCtD
Ondansetron—Constipation—Etoposide—uterine cancer	0.000302	0.00123	CcSEcCtD
Ondansetron—Urinary tract infection—Epirubicin—uterine cancer	0.000302	0.00123	CcSEcCtD
Ondansetron—Dysuria—Doxorubicin—uterine cancer	0.000301	0.00122	CcSEcCtD
Ondansetron—Hepatobiliary disease—Epirubicin—uterine cancer	0.000294	0.00119	CcSEcCtD
Ondansetron—Feeling abnormal—Etoposide—uterine cancer	0.000291	0.00118	CcSEcCtD
Ondansetron—Gastrointestinal pain—Etoposide—uterine cancer	0.000289	0.00117	CcSEcCtD
Ondansetron—Drowsiness—Doxorubicin—uterine cancer	0.000287	0.00117	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000285	0.00116	CcSEcCtD
Ondansetron—Bradycardia—Epirubicin—uterine cancer	0.000284	0.00115	CcSEcCtD
Ondansetron—Urticaria—Etoposide—uterine cancer	0.000281	0.00114	CcSEcCtD
Ondansetron—Haemoglobin—Epirubicin—uterine cancer	0.00028	0.00114	CcSEcCtD
Ondansetron—Body temperature increased—Etoposide—uterine cancer	0.000279	0.00113	CcSEcCtD
Ondansetron—Abdominal pain—Etoposide—uterine cancer	0.000279	0.00113	CcSEcCtD
Ondansetron—Urinary tract infection—Doxorubicin—uterine cancer	0.000279	0.00113	CcSEcCtD
Ondansetron—Haemorrhage—Epirubicin—uterine cancer	0.000279	0.00113	CcSEcCtD
Ondansetron—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000272	0.0011	CcSEcCtD
Ondansetron—Visual impairment—Epirubicin—uterine cancer	0.000269	0.00109	CcSEcCtD
Ondansetron—Erythema multiforme—Epirubicin—uterine cancer	0.000263	0.00107	CcSEcCtD
Ondansetron—Bradycardia—Doxorubicin—uterine cancer	0.000263	0.00107	CcSEcCtD
Ondansetron—Eye disorder—Epirubicin—uterine cancer	0.00026	0.00106	CcSEcCtD
Ondansetron—Hypersensitivity—Etoposide—uterine cancer	0.00026	0.00106	CcSEcCtD
Ondansetron—Haemoglobin—Doxorubicin—uterine cancer	0.000259	0.00105	CcSEcCtD
Ondansetron—Cardiac disorder—Epirubicin—uterine cancer	0.000259	0.00105	CcSEcCtD
Ondansetron—Flushing—Epirubicin—uterine cancer	0.000259	0.00105	CcSEcCtD
Ondansetron—Haemorrhage—Doxorubicin—uterine cancer	0.000258	0.00105	CcSEcCtD
Ondansetron—Asthenia—Etoposide—uterine cancer	0.000253	0.00103	CcSEcCtD
Ondansetron—Angiopathy—Epirubicin—uterine cancer	0.000253	0.00103	CcSEcCtD
Ondansetron—Immune system disorder—Epirubicin—uterine cancer	0.000252	0.00102	CcSEcCtD
Ondansetron—Mediastinal disorder—Epirubicin—uterine cancer	0.000251	0.00102	CcSEcCtD
Ondansetron—Chills—Epirubicin—uterine cancer	0.00025	0.00102	CcSEcCtD
Ondansetron—Pruritus—Etoposide—uterine cancer	0.00025	0.00102	CcSEcCtD
Ondansetron—Arrhythmia—Epirubicin—uterine cancer	0.000249	0.00101	CcSEcCtD
Ondansetron—Visual impairment—Doxorubicin—uterine cancer	0.000248	0.00101	CcSEcCtD
Ondansetron—Erythema multiforme—Doxorubicin—uterine cancer	0.000244	0.000991	CcSEcCtD
Ondansetron—Erythema—Epirubicin—uterine cancer	0.000243	0.000986	CcSEcCtD
Ondansetron—Diarrhoea—Etoposide—uterine cancer	0.000242	0.000982	CcSEcCtD
Ondansetron—Eye disorder—Doxorubicin—uterine cancer	0.000241	0.000979	CcSEcCtD
Ondansetron—Flushing—Doxorubicin—uterine cancer	0.000239	0.000972	CcSEcCtD
Ondansetron—Cardiac disorder—Doxorubicin—uterine cancer	0.000239	0.000972	CcSEcCtD
Ondansetron—Flatulence—Epirubicin—uterine cancer	0.000239	0.000971	CcSEcCtD
Ondansetron—Angiopathy—Doxorubicin—uterine cancer	0.000234	0.000951	CcSEcCtD
Ondansetron—Dizziness—Etoposide—uterine cancer	0.000234	0.000949	CcSEcCtD
Ondansetron—Immune system disorder—Doxorubicin—uterine cancer	0.000233	0.000946	CcSEcCtD
Ondansetron—Mediastinal disorder—Doxorubicin—uterine cancer	0.000232	0.000944	CcSEcCtD
Ondansetron—Chills—Doxorubicin—uterine cancer	0.000231	0.00094	CcSEcCtD
Ondansetron—Arrhythmia—Doxorubicin—uterine cancer	0.00023	0.000936	CcSEcCtD
Ondansetron—Vision blurred—Epirubicin—uterine cancer	0.000229	0.000929	CcSEcCtD
Ondansetron—Ill-defined disorder—Epirubicin—uterine cancer	0.000225	0.000915	CcSEcCtD
Ondansetron—Vomiting—Etoposide—uterine cancer	0.000225	0.000912	CcSEcCtD
Ondansetron—Erythema—Doxorubicin—uterine cancer	0.000224	0.000912	CcSEcCtD
Ondansetron—Agitation—Epirubicin—uterine cancer	0.000223	0.000906	CcSEcCtD
Ondansetron—Rash—Etoposide—uterine cancer	0.000223	0.000905	CcSEcCtD
Ondansetron—Dermatitis—Etoposide—uterine cancer	0.000222	0.000904	CcSEcCtD
Ondansetron—Headache—Etoposide—uterine cancer	0.000221	0.000899	CcSEcCtD
Ondansetron—Flatulence—Doxorubicin—uterine cancer	0.000221	0.000899	CcSEcCtD
Ondansetron—Malaise—Epirubicin—uterine cancer	0.000219	0.000889	CcSEcCtD
Ondansetron—Syncope—Epirubicin—uterine cancer	0.000218	0.000884	CcSEcCtD
Ondansetron—Palpitations—Epirubicin—uterine cancer	0.000214	0.000871	CcSEcCtD
Ondansetron—Loss of consciousness—Epirubicin—uterine cancer	0.000213	0.000866	CcSEcCtD
Ondansetron—Cough—Epirubicin—uterine cancer	0.000212	0.00086	CcSEcCtD
Ondansetron—Vision blurred—Doxorubicin—uterine cancer	0.000212	0.00086	CcSEcCtD
Ondansetron—Convulsion—Epirubicin—uterine cancer	0.00021	0.000854	CcSEcCtD
Ondansetron—Ill-defined disorder—Doxorubicin—uterine cancer	0.000208	0.000846	CcSEcCtD
Ondansetron—Chest pain—Epirubicin—uterine cancer	0.000207	0.000839	CcSEcCtD
Ondansetron—Agitation—Doxorubicin—uterine cancer	0.000206	0.000838	CcSEcCtD
Ondansetron—Anxiety—Epirubicin—uterine cancer	0.000206	0.000836	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000205	0.000833	CcSEcCtD
Ondansetron—Discomfort—Epirubicin—uterine cancer	0.000204	0.000829	CcSEcCtD
Ondansetron—Malaise—Doxorubicin—uterine cancer	0.000202	0.000822	CcSEcCtD
Ondansetron—Dry mouth—Epirubicin—uterine cancer	0.000202	0.000821	CcSEcCtD
Ondansetron—Syncope—Doxorubicin—uterine cancer	0.000201	0.000818	CcSEcCtD
Ondansetron—Palpitations—Doxorubicin—uterine cancer	0.000198	0.000806	CcSEcCtD
Ondansetron—Anaphylactic shock—Epirubicin—uterine cancer	0.000198	0.000804	CcSEcCtD
Ondansetron—Loss of consciousness—Doxorubicin—uterine cancer	0.000197	0.000802	CcSEcCtD
Ondansetron—Cough—Doxorubicin—uterine cancer	0.000196	0.000796	CcSEcCtD
Ondansetron—Shock—Epirubicin—uterine cancer	0.000195	0.000791	CcSEcCtD
Ondansetron—Convulsion—Doxorubicin—uterine cancer	0.000194	0.00079	CcSEcCtD
Ondansetron—Nervous system disorder—Epirubicin—uterine cancer	0.000194	0.000789	CcSEcCtD
Ondansetron—Tachycardia—Epirubicin—uterine cancer	0.000193	0.000785	CcSEcCtD
Ondansetron—Skin disorder—Epirubicin—uterine cancer	0.000192	0.000781	CcSEcCtD
Ondansetron—Chest pain—Doxorubicin—uterine cancer	0.000191	0.000776	CcSEcCtD
Ondansetron—Anxiety—Doxorubicin—uterine cancer	0.00019	0.000774	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.00019	0.000771	CcSEcCtD
Ondansetron—Discomfort—Doxorubicin—uterine cancer	0.000189	0.000767	CcSEcCtD
Ondansetron—Dry mouth—Doxorubicin—uterine cancer	0.000187	0.000759	CcSEcCtD
Ondansetron—Hypotension—Epirubicin—uterine cancer	0.000185	0.000752	CcSEcCtD
Ondansetron—Anaphylactic shock—Doxorubicin—uterine cancer	0.000183	0.000744	CcSEcCtD
Ondansetron—Shock—Doxorubicin—uterine cancer	0.00018	0.000732	CcSEcCtD
Ondansetron—Nervous system disorder—Doxorubicin—uterine cancer	0.00018	0.00073	CcSEcCtD
Ondansetron—Tachycardia—Doxorubicin—uterine cancer	0.000179	0.000726	CcSEcCtD
Ondansetron—Skin disorder—Doxorubicin—uterine cancer	0.000178	0.000723	CcSEcCtD
Ondansetron—Paraesthesia—Epirubicin—uterine cancer	0.000178	0.000722	CcSEcCtD
Ondansetron—Dyspnoea—Epirubicin—uterine cancer	0.000177	0.000717	CcSEcCtD
Ondansetron—Somnolence—Epirubicin—uterine cancer	0.000176	0.000715	CcSEcCtD
Ondansetron—Hypotension—Doxorubicin—uterine cancer	0.000171	0.000696	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000171	0.000695	CcSEcCtD
Ondansetron—Fatigue—Epirubicin—uterine cancer	0.000171	0.000694	CcSEcCtD
Ondansetron—Pain—Epirubicin—uterine cancer	0.000169	0.000688	CcSEcCtD
Ondansetron—Constipation—Epirubicin—uterine cancer	0.000169	0.000688	CcSEcCtD
Ondansetron—Paraesthesia—Doxorubicin—uterine cancer	0.000164	0.000668	CcSEcCtD
Ondansetron—Dyspnoea—Doxorubicin—uterine cancer	0.000163	0.000664	CcSEcCtD
Ondansetron—Feeling abnormal—Epirubicin—uterine cancer	0.000163	0.000663	CcSEcCtD
Ondansetron—Somnolence—Doxorubicin—uterine cancer	0.000163	0.000662	CcSEcCtD
Ondansetron—Gastrointestinal pain—Epirubicin—uterine cancer	0.000162	0.000658	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000158	0.000643	CcSEcCtD
Ondansetron—Fatigue—Doxorubicin—uterine cancer	0.000158	0.000642	CcSEcCtD
Ondansetron—Urticaria—Epirubicin—uterine cancer	0.000157	0.000639	CcSEcCtD
Ondansetron—Pain—Doxorubicin—uterine cancer	0.000157	0.000637	CcSEcCtD
Ondansetron—Constipation—Doxorubicin—uterine cancer	0.000157	0.000637	CcSEcCtD
Ondansetron—Body temperature increased—Epirubicin—uterine cancer	0.000157	0.000636	CcSEcCtD
Ondansetron—Abdominal pain—Epirubicin—uterine cancer	0.000157	0.000636	CcSEcCtD
Ondansetron—Feeling abnormal—Doxorubicin—uterine cancer	0.000151	0.000613	CcSEcCtD
Ondansetron—Gastrointestinal pain—Doxorubicin—uterine cancer	0.00015	0.000609	CcSEcCtD
Ondansetron—Hypersensitivity—Epirubicin—uterine cancer	0.000146	0.000593	CcSEcCtD
Ondansetron—Urticaria—Doxorubicin—uterine cancer	0.000146	0.000591	CcSEcCtD
Ondansetron—Abdominal pain—Doxorubicin—uterine cancer	0.000145	0.000588	CcSEcCtD
Ondansetron—Body temperature increased—Doxorubicin—uterine cancer	0.000145	0.000588	CcSEcCtD
Ondansetron—Asthenia—Epirubicin—uterine cancer	0.000142	0.000577	CcSEcCtD
Ondansetron—Pruritus—Epirubicin—uterine cancer	0.00014	0.000569	CcSEcCtD
Ondansetron—Diarrhoea—Epirubicin—uterine cancer	0.000135	0.00055	CcSEcCtD
Ondansetron—Hypersensitivity—Doxorubicin—uterine cancer	0.000135	0.000548	CcSEcCtD
Ondansetron—Asthenia—Doxorubicin—uterine cancer	0.000131	0.000534	CcSEcCtD
Ondansetron—Dizziness—Epirubicin—uterine cancer	0.000131	0.000532	CcSEcCtD
Ondansetron—Pruritus—Doxorubicin—uterine cancer	0.00013	0.000527	CcSEcCtD
Ondansetron—Vomiting—Epirubicin—uterine cancer	0.000126	0.000511	CcSEcCtD
Ondansetron—Diarrhoea—Doxorubicin—uterine cancer	0.000125	0.000509	CcSEcCtD
Ondansetron—Rash—Epirubicin—uterine cancer	0.000125	0.000507	CcSEcCtD
Ondansetron—Dermatitis—Epirubicin—uterine cancer	0.000125	0.000507	CcSEcCtD
Ondansetron—Headache—Epirubicin—uterine cancer	0.000124	0.000504	CcSEcCtD
Ondansetron—Dizziness—Doxorubicin—uterine cancer	0.000121	0.000492	CcSEcCtD
Ondansetron—Vomiting—Doxorubicin—uterine cancer	0.000116	0.000473	CcSEcCtD
Ondansetron—Rash—Doxorubicin—uterine cancer	0.000116	0.000469	CcSEcCtD
Ondansetron—Dermatitis—Doxorubicin—uterine cancer	0.000115	0.000469	CcSEcCtD
Ondansetron—Headache—Doxorubicin—uterine cancer	0.000115	0.000466	CcSEcCtD
Ondansetron—CYP3A5—Metabolism—STAR—uterine cancer	3.04e-06	0.00102	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.02e-06	0.00101	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CCL2—uterine cancer	3.01e-06	0.00101	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKR1C1—uterine cancer	3e-06	0.00101	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—NDUFB11—uterine cancer	2.99e-06	0.001	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SRD5A2—uterine cancer	2.99e-06	0.001	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SRD5A2—uterine cancer	2.96e-06	0.000995	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—NDUFB11—uterine cancer	2.96e-06	0.000995	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.88e-06	0.000967	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—INHBA—uterine cancer	2.88e-06	0.000966	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CCL2—uterine cancer	2.87e-06	0.000964	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CXCL8—uterine cancer	2.76e-06	0.000927	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—RRM2—uterine cancer	2.75e-06	0.000924	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.72e-06	0.000913	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—PIK3CA—uterine cancer	2.68e-06	0.000901	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—DCN—uterine cancer	2.67e-06	0.000897	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—KRAS—uterine cancer	2.65e-06	0.000891	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKR1C3—uterine cancer	2.62e-06	0.000879	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKR1C1—uterine cancer	2.59e-06	0.00087	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PGR—uterine cancer	2.55e-06	0.000856	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—NDUFB11—uterine cancer	2.53e-06	0.00085	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SRD5A2—uterine cancer	2.53e-06	0.00085	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP11A1—uterine cancer	2.51e-06	0.000845	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.46e-06	0.000826	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—PIK3CA—uterine cancer	2.44e-06	0.000818	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—YWHAE—uterine cancer	2.43e-06	0.000817	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ERBB2—uterine cancer	2.39e-06	0.000803	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—POLD1—uterine cancer	2.39e-06	0.000803	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—POLD1—uterine cancer	2.38e-06	0.000801	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CXCL8—uterine cancer	2.38e-06	0.0008	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKR1C3—uterine cancer	2.37e-06	0.000798	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—FBXW7—uterine cancer	2.33e-06	0.000783	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.32e-06	0.00078	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKR1C3—uterine cancer	2.31e-06	0.000776	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CXCL8—uterine cancer	2.27e-06	0.000762	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—HRAS—uterine cancer	2.25e-06	0.000757	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PGR—uterine cancer	2.25e-06	0.000756	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKR1C1—uterine cancer	2.23e-06	0.000751	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKR1C1—uterine cancer	2.23e-06	0.000749	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CDKN1B—uterine cancer	2.21e-06	0.000744	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—AKT1—uterine cancer	2.19e-06	0.000736	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKR1B1—uterine cancer	2.16e-06	0.000726	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—STAR—uterine cancer	2.16e-06	0.000726	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—YWHAE—uterine cancer	2.15e-06	0.000721	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKR1B1—uterine cancer	2.14e-06	0.000719	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—STAR—uterine cancer	2.14e-06	0.000719	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.12e-06	0.000711	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CTNNB1—uterine cancer	2.09e-06	0.000703	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—FBXW7—uterine cancer	2.06e-06	0.000691	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PTEN—uterine cancer	2.04e-06	0.000685	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—STK11—uterine cancer	2.04e-06	0.000685	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CCL2—uterine cancer	2.03e-06	0.000682	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKR1C3—uterine cancer	1.99e-06	0.00067	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—RRM2—uterine cancer	1.99e-06	0.000669	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—AKT1—uterine cancer	1.99e-06	0.000668	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—RRM2—uterine cancer	1.99e-06	0.000668	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SRD5A2—uterine cancer	1.95e-06	0.000656	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—NDUFB11—uterine cancer	1.95e-06	0.000656	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EP300—uterine cancer	1.94e-06	0.000653	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PGR—uterine cancer	1.94e-06	0.000652	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—DCN—uterine cancer	1.93e-06	0.00065	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—DCN—uterine cancer	1.93e-06	0.000648	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SOCS3—uterine cancer	1.91e-06	0.000641	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—YWHAE—uterine cancer	1.85e-06	0.000622	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—STK11—uterine cancer	1.85e-06	0.000622	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CYP19A1—uterine cancer	1.85e-06	0.000622	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—VEGFA—uterine cancer	1.84e-06	0.000619	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—STAR—uterine cancer	1.83e-06	0.000615	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKR1B1—uterine cancer	1.83e-06	0.000615	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN2B—uterine cancer	1.83e-06	0.000614	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP11A1—uterine cancer	1.82e-06	0.000612	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—NRAS—uterine cancer	1.82e-06	0.000611	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP11A1—uterine cancer	1.82e-06	0.000611	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.81e-06	0.000608	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—STK11—uterine cancer	1.8e-06	0.000604	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CCL2—uterine cancer	1.79e-06	0.000602	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FBXW7—uterine cancer	1.78e-06	0.000597	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—IGF1R—uterine cancer	1.77e-06	0.000596	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CXCL8—uterine cancer	1.77e-06	0.000593	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKR1C3—uterine cancer	1.72e-06	0.000578	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKR1C3—uterine cancer	1.72e-06	0.000577	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—POLD1—uterine cancer	1.7e-06	0.000569	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SOCS3—uterine cancer	1.68e-06	0.000566	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—POLD1—uterine cancer	1.68e-06	0.000565	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—SMAD3—uterine cancer	1.67e-06	0.00056	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN2B—uterine cancer	1.61e-06	0.000542	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CXCL8—uterine cancer	1.6e-06	0.000539	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—FGFR2—uterine cancer	1.59e-06	0.000535	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.59e-06	0.000533	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.57e-06	0.000528	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—KRAS—uterine cancer	1.57e-06	0.000526	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—IGF1R—uterine cancer	1.57e-06	0.000526	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCL8—uterine cancer	1.56e-06	0.000524	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—STK11—uterine cancer	1.55e-06	0.000522	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CCL2—uterine cancer	1.55e-06	0.000519	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—SMAD3—uterine cancer	1.47e-06	0.000495	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SOCS3—uterine cancer	1.45e-06	0.000488	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PIK3CA—uterine cancer	1.44e-06	0.000483	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—POLD1—uterine cancer	1.44e-06	0.000482	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCL8—uterine cancer	1.42e-06	0.000476	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—RRM2—uterine cancer	1.41e-06	0.000475	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKR1B1—uterine cancer	1.41e-06	0.000474	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—STAR—uterine cancer	1.41e-06	0.000474	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—FGFR2—uterine cancer	1.4e-06	0.000472	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—RRM2—uterine cancer	1.4e-06	0.000471	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN2B—uterine cancer	1.39e-06	0.000468	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—TP53—uterine cancer	1.39e-06	0.000468	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—MTHFR—uterine cancer	1.39e-06	0.000467	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—DCN—uterine cancer	1.37e-06	0.000461	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ESR1—uterine cancer	1.36e-06	0.000457	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—DCN—uterine cancer	1.36e-06	0.000457	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—IGF1R—uterine cancer	1.35e-06	0.000454	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCL8—uterine cancer	1.35e-06	0.000452	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKR1C1—uterine cancer	1.34e-06	0.000451	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—STK11—uterine cancer	1.34e-06	0.00045	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CYP19A1—uterine cancer	1.34e-06	0.00045	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—STK11—uterine cancer	1.34e-06	0.000449	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CYP19A1—uterine cancer	1.34e-06	0.000449	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HRAS—uterine cancer	1.33e-06	0.000447	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.29e-06	0.000434	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—NRAS—uterine cancer	1.29e-06	0.000432	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.28e-06	0.00043	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—SMAD3—uterine cancer	1.27e-06	0.000427	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL8—uterine cancer	1.22e-06	0.00041	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.22e-06	0.00041	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—FGFR2—uterine cancer	1.21e-06	0.000407	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.21e-06	0.000407	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ESR1—uterine cancer	1.2e-06	0.000404	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CCL2—uterine cancer	1.2e-06	0.000403	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—RRM2—uterine cancer	1.2e-06	0.000402	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AKT1—uterine cancer	1.18e-06	0.000395	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—DCN—uterine cancer	1.16e-06	0.00039	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—NRAS—uterine cancer	1.14e-06	0.000382	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—PIK3CA—uterine cancer	1.12e-06	0.000376	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—POLD1—uterine cancer	1.11e-06	0.000372	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—KRAS—uterine cancer	1.11e-06	0.000372	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP11A1—uterine cancer	1.1e-06	0.000368	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CCL2—uterine cancer	1.06e-06	0.000355	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ESR1—uterine cancer	1.04e-06	0.000348	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKR1C1—uterine cancer	1.04e-06	0.000348	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKR1C3—uterine cancer	1.03e-06	0.000347	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—PIK3CA—uterine cancer	1.02e-06	0.000342	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—MTHFR—uterine cancer	1.01e-06	0.000338	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—MTHFR—uterine cancer	1e-06	0.000338	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ERBB2—uterine cancer	9.99e-07	0.000336	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—PIK3CA—uterine cancer	9.89e-07	0.000332	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—NRAS—uterine cancer	9.8e-07	0.000329	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—KRAS—uterine cancer	9.77e-07	0.000328	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—STK11—uterine cancer	9.51e-07	0.000319	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CYP19A1—uterine cancer	9.51e-07	0.000319	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL8—uterine cancer	9.48e-07	0.000318	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—STK11—uterine cancer	9.43e-07	0.000317	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CYP19A1—uterine cancer	9.43e-07	0.000317	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HRAS—uterine cancer	9.41e-07	0.000316	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CDKN1B—uterine cancer	9.25e-07	0.000311	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—RRM2—uterine cancer	9.24e-07	0.00031	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AKT1—uterine cancer	9.15e-07	0.000308	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CCL2—uterine cancer	9.13e-07	0.000307	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—PIK3CA—uterine cancer	8.98e-07	0.000302	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—DCN—uterine cancer	8.97e-07	0.000301	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	8.85e-07	0.000297	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ERBB2—uterine cancer	8.82e-07	0.000296	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CTNNB1—uterine cancer	8.74e-07	0.000294	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—PIK3CA—uterine cancer	8.54e-07	0.000287	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PTEN—uterine cancer	8.52e-07	0.000286	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP11A1—uterine cancer	8.45e-07	0.000284	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	8.44e-07	0.000284	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—KRAS—uterine cancer	8.44e-07	0.000283	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL8—uterine cancer	8.36e-07	0.000281	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AKT1—uterine cancer	8.31e-07	0.000279	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HRAS—uterine cancer	8.31e-07	0.000279	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CDKN1B—uterine cancer	8.17e-07	0.000274	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EP300—uterine cancer	8.13e-07	0.000273	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AKT1—uterine cancer	8.08e-07	0.000271	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—STK11—uterine cancer	8.06e-07	0.000271	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CYP19A1—uterine cancer	8.06e-07	0.000271	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKR1C3—uterine cancer	7.98e-07	0.000268	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—PIK3CA—uterine cancer	7.75e-07	0.00026	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PTEN—uterine cancer	7.73e-07	0.00026	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CTNNB1—uterine cancer	7.72e-07	0.000259	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—VEGFA—uterine cancer	7.7e-07	0.000259	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ERBB2—uterine cancer	7.61e-07	0.000256	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—NRAS—uterine cancer	7.6e-07	0.000255	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.56e-07	0.000254	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PTEN—uterine cancer	7.52e-07	0.000253	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—EP300—uterine cancer	7.38e-07	0.000248	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AKT1—uterine cancer	7.34e-07	0.000246	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL8—uterine cancer	7.22e-07	0.000242	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.21e-07	0.000242	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HRAS—uterine cancer	7.17e-07	0.000241	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EP300—uterine cancer	7.17e-07	0.000241	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—MTHFR—uterine cancer	7.15e-07	0.00024	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—MTHFR—uterine cancer	7.08e-07	0.000238	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CDKN1B—uterine cancer	7.05e-07	0.000237	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AKT1—uterine cancer	6.97e-07	0.000234	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—VEGFA—uterine cancer	6.79e-07	0.000228	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—NRAS—uterine cancer	6.71e-07	0.000225	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CTNNB1—uterine cancer	6.66e-07	0.000224	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—KRAS—uterine cancer	6.54e-07	0.00022	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PTEN—uterine cancer	6.49e-07	0.000218	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AKT1—uterine cancer	6.33e-07	0.000213	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.24e-07	0.00021	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—STK11—uterine cancer	6.22e-07	0.000209	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CYP19A1—uterine cancer	6.22e-07	0.000209	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EP300—uterine cancer	6.19e-07	0.000208	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—MTHFR—uterine cancer	6.05e-07	0.000203	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PIK3CA—uterine cancer	6.01e-07	0.000202	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—VEGFA—uterine cancer	5.86e-07	0.000197	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—TP53—uterine cancer	5.81e-07	0.000195	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—NRAS—uterine cancer	5.79e-07	0.000195	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—KRAS—uterine cancer	5.77e-07	0.000194	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PTEN—uterine cancer	5.6e-07	0.000188	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PTEN—uterine cancer	5.59e-07	0.000188	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HRAS—uterine cancer	5.56e-07	0.000187	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—PIK3CA—uterine cancer	5.46e-07	0.000183	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—EP300—uterine cancer	5.34e-07	0.000179	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.33e-07	0.000179	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—EP300—uterine cancer	5.33e-07	0.000179	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PIK3CA—uterine cancer	5.3e-07	0.000178	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—TP53—uterine cancer	5.13e-07	0.000172	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—KRAS—uterine cancer	4.98e-07	0.000167	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AKT1—uterine cancer	4.91e-07	0.000165	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HRAS—uterine cancer	4.91e-07	0.000165	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—MTHFR—uterine cancer	4.67e-07	0.000157	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PIK3CA—uterine cancer	4.58e-07	0.000154	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AKT1—uterine cancer	4.46e-07	0.00015	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—TP53—uterine cancer	4.43e-07	0.000149	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AKT1—uterine cancer	4.33e-07	0.000146	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HRAS—uterine cancer	4.24e-07	0.000142	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PTEN—uterine cancer	3.98e-07	0.000134	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—PIK3CA—uterine cancer	3.95e-07	0.000133	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—PIK3CA—uterine cancer	3.94e-07	0.000133	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PTEN—uterine cancer	3.94e-07	0.000132	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—EP300—uterine cancer	3.79e-07	0.000127	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—EP300—uterine cancer	3.76e-07	0.000126	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AKT1—uterine cancer	3.74e-07	0.000126	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PTEN—uterine cancer	3.37e-07	0.000113	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AKT1—uterine cancer	3.23e-07	0.000108	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AKT1—uterine cancer	3.22e-07	0.000108	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—EP300—uterine cancer	3.21e-07	0.000108	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—PIK3CA—uterine cancer	2.8e-07	9.42e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—PIK3CA—uterine cancer	2.78e-07	9.34e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PTEN—uterine cancer	2.6e-07	8.73e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—EP300—uterine cancer	2.48e-07	8.33e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—PIK3CA—uterine cancer	2.38e-07	7.98e-05	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AKT1—uterine cancer	2.29e-07	7.7e-05	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AKT1—uterine cancer	2.27e-07	7.63e-05	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AKT1—uterine cancer	1.94e-07	6.52e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.83e-07	6.16e-05	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AKT1—uterine cancer	1.5e-07	5.03e-05	CbGpPWpGaD
